PRINT THIS PAGE 3i realises investment in Swedish biotech company Arexis22/08/2005. Source: AltAssets. 
 3i Group, along with syndicate members, SEB Företagsinvest, InnovationsKapital and Industrifonden, has agreed to divest its 26 per cent undiluted stake in Swedish biotech company Arexis in an acquisition by European biotechnology firms Biovitrum. Financial terms of the transaction have not been disclosed.
Arexis, founded in 1999, specialises in the development of pharmaceuticals for the treatment of metabolic and inflammatory diseases, for example diabetes and rheumatoid arthritis.
Thomas Pollare, director, 3i Nordic and advisor to 3i Group, said, 'It has been a pleasure working with Arexis' excellent management team to support the company's development over the last four years. Since our first investment in 2001, the company has developed from research into a company with an attractive portfolio of clinical projects. In Biovitrum, Arexis has gained a strong industrial owner who will support and accelerate its future growth significantly.'
3i focuses on buy-outs, growth capital and venture capital, and invests across Europe, in the United States and in Asia Pacific.
Copyright © 2005 AltAssets
|
